Clinical trial · Observational
Establishing a Tumor Registry of Patients With Mesonephric-like Adenocarcinoma (MLA)
NCT06377527CI-TRIAL-00118862recruitingClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
To develop a database of medical information about patients with MLA in an effort to increase our understanding of the characteristics of MLA, which is the rarest form of endometrial carcinoma.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Mesonephric-like Adenocarcinoma | Mesonephric-Like Adenocarcinoma | ONTOLOGY_EXACT | 0.98 |
Interventions
Interventions (0)
Data not yet available
No intervention recorded.
Design
Arms and outcomes
Arms (1)
- label
- Mesonephric-like Adenocarcinoma (MLA)
- description
- Particpants who agree to take part in this research, information such as your demographics (including your name, date of birth, race, etc.), medical history, surgical history, family history, social history, cancer diagnosis, primary treatment, and follow up will be collected. Participants also have the option to agree to the use of your previously collected tumor tissue samples for future research to better understand MLA.
Primary outcomes (1)
- measure
- Tumor Registry
- timeFrame
- Through study completion; an average of 1 year
- description
- The goal of this data collection study is to develop a database (i.e. a registry/repository) of medical information about patients with MLA in an effort to increase our understanding of the characteristics of MLA, which is the rarest form of endometrial carcinoma.
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: 1. Adult patients over the age of 18. 2. Patients with a diagnosis of gynecologic mesonephric-like adenocarcinoma (MLA), mesonephric adenocarcinoma (MA), mesonephric carcinosarcoma, or mesonephric-like carcinosarcomas. 3. For patients who provide consent, they must speak and/or read English or Spanish. Exclusion Criteria: 1. Patients with other subtypes of EACs. 2. Patients who are considered cognitively impaired. Assessment will be obtained based on their need of a Legally Authorized Representative.
References
Publications (0)
Data not yet available
No reference posted for this study.